Evidence map›Paper›PMID 42138195›Full record

ArticleOncology reports2026

[Corrigendum] ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune micro-environment.

Wei-Jie Chen, Wei Yang, Min Gong, Yi He, Da Xu, Jia-Xin Chen, Wen-Jin Chen, Wen-Yan Li, Yu-Qi Wang, Ke-Qin Dong and 3 more

Abstract readPublished Erratum
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Wei-Jie ChenDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Wei YangDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Min GongDepartment of Urology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China.
Yi HeDepartment of Urology, Jiaxing First Hospital, Jiaxing, Zhejiang 314001, P.R. China.
Da XuDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Jia-Xin ChenDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Wen-Jin ChenDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Wen-Yan LiDepartment of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China.
Yu-Qi WangDepartment of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China.
Ke-Qin DongDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Xu SongDepartment of Urology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China.
Xiu-Wu PanDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.
Xin-Gang CuiDepartment of Urology, Third Affiliated Hospital of The Second Military Medical University, Shanghai 200433, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this article, the authors have brought to the Editor's attention that they made an error in the compilation of the data in Fig. 4, as it appeared on p. 9. Specifically, some of the blots included for the 769‑P cell line experiments in Fig. 4B had inadvertently been included in the figure incorrectly. The corrected version of Fig. 4, now showing all the correct western blot data in Fig. 4B, is shown on the next page. The authors sincerely apologize for the errors that were introduced during the preparation of this figure, and are grateful to the Editor of

Indexed as

cancer progressionclear cell renal cell carcinomaenolase 2epithelial‑mesenchymal transitionimmune checkpoint therapyimmune microenvironmentprognosis

Identifiers

PMID42138195
PMCPMC13195262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.